This investment will mark Cipla’s strategic participation in the PoC diagnostics and AMR (antimicrobial resistance) space through the design, development, and manufacturing of microfluidics-based technologies.
Achin Gupta, CEO of Cipla's One India Business, commented, "This investment will help us meet our goal of providing innovative, cheap, and high-quality diagnostic solutions to everyone. We will continue to make strategic investments to enable access to point-of-care test kit solutions, inspired by our goal of Caring for Life."
A Proof of Concept (PoC) that allows for the fast identification of the bug causing an illness would be highly useful in selecting the proper antibiotic early in the treatment process.
This transaction will be completed within a period of 60 days from the signing of the definitive agreement by the company.
Achira is engaged in the development and commercialization of point of care (PoC) medical test kits in India. It is a medical diagnostics firm that uses microfluidic technology to produce medical diagnostic solutions that bring complex medical testing closer to the point of diagnosis, treatment, and management.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.